马里疟原虫对当前及候选抗疟药的体外敏感性比较
该研究在马里对PCR确诊的单一感染间日疟原虫和恶性疟原虫进行体外药物敏感性评估,发现间日疟原虫感染频率为3%-15%,且对氯喹、苯芴醇和蒿甲醚的体外敏感性显著降低。哌喹、GNF179和KDU691对两种疟原虫均显示强抑制作用,提示氯喹、苯芴醇和蒿甲醚可能不适合治疗间日疟原虫感染。
要点
- 间日疟原虫感染频率为3%-15%,对氯喹、苯芴醇和蒿甲醚体外敏感性显著降低。
- 哌喹对间日疟原虫和恶性疟原虫均显示强抑制作用。
- GNF179和KDU691对间日疟原虫和恶性疟原虫均高度抑制。
核心结论
- 氯喹、苯芴醇和蒿甲醚可能不适合治疗间日疟原虫感染。
- 哌喹以及新型抗疟药咪唑哌嗪类和PI4K特异性抑制剂具有治愈间日疟原虫的潜力。
研究设计与样本
- 横断面筛查嵌套于纵向前瞻性研究,检测所有疟原虫虫种病例。
- 对PCR确诊的间日疟原虫和恶性疟原虫单一感染进行体外药物敏感性评估。
主要发现
- 间日疟原虫感染频率为3%-15%。
- 间日疟原虫对氯喹、苯芴醇和蒿甲醚的体外敏感性显著降低。
- 哌喹对间日疟原虫和恶性疟原虫均显示强抑制作用。
- GNF179(KAF156的密切类似物)对间日疟原虫显示强抑制作用。
- PI4K特异性抑制剂KDU691对间日疟原虫和恶性疟原虫均高度抑制。
关键数值与推荐
- 检测药物包括氯喹、苯芴醇、蒿甲醚、哌喹、GNF179和KDU691。
- GNF179为咪唑哌嗪类,是KAF156的密切类似物,KAF156处于临床IIb期测试。
- KDU691为疟原虫PI4K特异性抑制剂。
临床怎么用
- 间日疟原虫感染治疗应避免使用氯喹、苯芴醇和蒿甲醚。
- 哌喹可作为治疗间日疟原虫感染的潜在选择。
- 新型抗疟药咪唑哌嗪类和PI4K特异性抑制剂值得进一步临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate Plasmodium malariae susceptibility to current and lead candidate antimalarial drugs. METHODS: We conducted cross-sectional screening and detection of all Plasmodium species malaria cases, which were nested within a longitudinal prospective study, and an ex vivo assessment of efficacy of a panel of antimalarials against P. malariae and Plasmodium falciparum, both PCR-confirmed mono-infections. Reference compounds tested included chloroquine, lumefantrine, artemether and piperaquine, while candidate antimalarials included the imidazolopiperazine GNF179, a close analogue of KAF156, and the Plasmodium phosphatidylinositol-4-OH kinase (PI4K)-specific inhibitor KDU691. RESULTS: We report a high frequency (3%-15%) of P. malariae infections with a significant reduction in ex vivo susceptibility to chloroquine, lumefantrine and artemether, which are the current frontline drugs against P. malariae infections. Unlike these compounds, potent inhibition of P. malariae and P. falciparum was observed with piperaquine exposure. Furthermore, we evaluated advanced lead antimalarial compounds. In this regard, we identified strong inhibition of P. malariae using GNF179, a close analogue of KAF156 imidazolopiperazines, which is a novel class of antimalarial drug currently in clinical Phase IIb testing. Finally, in addition to GNF179, we demonstrated that the Plasmodium PI4K-specific inhibitor KDU691 is highly inhibitory against P. malariae and P. falciparum. CONCLUSIONS: Our data indicated that chloroquine, lumefantrine and artemether may not be suitable for the treatment of P. malariae infections and the potential of piperaquine, as well as new antimalarials imidazolopiperazines and PI4K-specific inhibitor, for P. malariae cure.
引用
- Dembele L, Aniweh Y, Diallo N, et al. Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali. J Antimicrob Chemother. 2021. PMID: 34021751. doi:10.1093/jac/dkab133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。